• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유
• 

Personalized Depression Treatment

Traditional treatment and medications don't work for a majority of patients suffering from depression. A customized treatment could be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into customized micro-interventions that improve mental health. We looked at the best-fitting personal ML models to each subject, using Shapley values to determine their features and predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only about half of people suffering from the condition receive treatment1. To improve the outcomes, healthcare professionals must be able to recognize and treat patients who have the highest chance of responding to specific treatments.

Personalized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most effective treatment for depression from certain treatments. They make use of sensors for mobile phones, a voice assistant with artificial intelligence, and other digital tools. Two grants totaling more than $10 million will be used to determine the biological and behavioral factors that predict response.

So far, the majority of research on factors that predict depression treatment effectiveness (Https://mozillabd.science/wiki/Why_You_Should_Focus_On_Improving_Depression_Treatment_And_Recovery) has centered on sociodemographic and clinical characteristics. These include demographic factors such as age, gender and education, clinical characteristics including the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

Very few studies have used longitudinal data to predict mood in individuals. They have not taken into account the fact that moods vary significantly between individuals. Therefore, it is critical to create methods that allow the recognition of the individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to recognize patterns of behaviour and emotions that are unique to each individual.

The team also devised an algorithm for machine learning to model dynamic predictors for the mood of each person's depression. The algorithm integrates the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of Symptoms

Depression is the most common reason for disability across the world1, but it is often not properly diagnosed and treated. In addition the absence of effective interventions and stigma associated with depressive disorders stop many people from seeking help.

To aid in the development of a personalized treatment plan, identifying predictors of symptoms is important. The current methods for predicting symptoms rely heavily on clinical interviews, which are not reliable and only identify a handful of symptoms associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous digital behavioral phenotypes gathered from smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to capture a large number of unique actions and behaviors that are difficult to capture through interviews and permit continuous and high-resolution measurements.

The study enrolled University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical natural treatment for depression depending on the degree of their depression. Those with a score on the CAT-DI scale of 35 65 students were assigned online support via an instructor and those with scores of 75 patients were referred to in-person clinics for psychotherapy.

At the beginning, participants answered the answers to a series of questions concerning their personal demographics and psychosocial characteristics. The questions covered age, sex and education and financial status, marital status, whether they were divorced or not, their current suicidal thoughts, intent or attempts, and how often they drank. Participants also rated their degree of depression severity on a scale ranging from 0-100 using the CAT-DI. CAT-DI assessments were conducted every week for those who received online support and once a week for those receiving in-person care.

Predictors of the Reaction to Treatment

Research is focusing on personalization of depression treatment. Many studies are aimed at finding predictors, which can aid clinicians in identifying the most effective drugs for each person. Pharmacogenetics in particular uncovers genetic variations that affect the way that our bodies process drugs. This allows doctors select medications that are likely to be the most effective for each patient, reducing time and effort spent on trial-and error treatments and eliminating any adverse consequences.

Another promising approach is to develop prediction models combining clinical data and neural imaging data. These models can be used to identify which variables are most likely to predict a specific outcome, such as whether a medication can improve symptoms or mood. These models can also be used to predict the patient's response to treatment that is already in place, allowing doctors to maximize the effectiveness of current treatment.

A new generation employs machine learning methods such as the supervised and classification algorithms such as regularized logistic regression, and tree-based methods to integrate the effects of several variables and improve predictive accuracy. These models have shown to be effective in the prediction of tms treatment for depression outcomes like the response to antidepressants. These methods are becoming more popular in psychiatry and could become the standard of future treatment.

In addition to ML-based prediction models The study of the underlying mechanisms of depression continues. Recent research suggests that depression is linked to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment for depression will depend on targeted therapies that restore normal function to these circuits.

One way to do this is to use internet-based interventions which can offer an personalized and customized experience for patients. For example, one study found that a web-based program was more effective than standard care in improving symptoms and providing a better quality of life for those suffering from MDD. Additionally, a randomized controlled trial of a personalized approach to depression treatment showed an improvement in symptoms and fewer side effects in a significant number of participants.

Predictors of adverse effects

A major issue in personalizing depression treatment is predicting the antidepressant medications that will have the least amount of side effects or none at all. Many patients have a trial-and error method, involving various medications prescribed until they find one that is safe and effective. Pharmacogenetics offers a fresh and exciting way to select antidepressant medications that is more efficient and targeted.

There are many predictors that can be used to determine which antidepressant should be prescribed, including genetic variations, phenotypes of patients such as ethnicity or gender, and co-morbidities. However, identifying the most reliable and valid predictive factors for a specific treatment will probably require randomized controlled trials of much larger samples than those typically enrolled in clinical trials. This is due to the fact that the identification of interaction effects or moderators may be much more difficult in trials that take into account a single episode of treatment per participant, rather than multiple episodes of treatment over time.

In addition the prediction of a patient's response will likely require information on comorbidities, symptom profiles and the patient's subjective perception of the effectiveness and tolerability. At present, only a handful of easily identifiable sociodemographic variables and clinical variables are reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

Many issues remain to be resolved when it comes to the use of pharmacogenetics for depression treatment. First, it is important to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression, as well as an understanding of a reliable indicator of the response to treatment. In addition, ethical concerns like privacy and the ethical use of personal genetic information, must be considered carefully. Pharmacogenetics could, in the long run, reduce stigma surrounding mental health treatments and improve treatment outcomes. Like any other psychiatric treatment it is essential to take your time and carefully implement the plan. At present, it's ideal to offer patients a variety of medications for depression that are effective and encourage them to talk openly with their physicians.